Development and preclinical efficacy of novel transforming growth factor-β1 short interfering RNAs for pulmonary fibrosis

Corina N. D'Alessandro-Gabazza, Tetsu Kobayashi, Daniel Boveda-Ruiz, Takehiro Takagi, Masaaki Toda, Paloma Gil-Bernabe, Yasushi Miyake, Atsushi Yasukawa, Yoshikazu Matsuda, Noboru Suzuki, Hiromitsu Saito, Yutaka Yano, Ayako Fukuda, Tetsuya Hasegawa, Hidekazu Toyobuku, Stephen I. Rennard, Peter D. Wagner, John Morser, Yoshiyuki Takei, Osamu TaguchiEsteban C. Gabazza

Research output: Contribution to journalArticlepeer-review

45 Scopus citations


Idiopathic pulmonary fibrosis is a chronic devastating disease of unknown etiology.Notherapy is currently available.Agrowingbody of evidence supports the role of transforming growth factor (TGF)- β1 as the major player in the pathogenesis of the disease. However, attempts to control its expression and to improve the outcome of pulmonary fibrosis have been disappointing. We tested the hypothesis that TGF-β1 is the dominant factor in the acute and chronic phases of pulmonary fibrosis and developed short interfering (si) RNAsdirectedtowardmolecules implicated in the disease. This study developed novel sequences of siRNAs targeting the TGF-β1 gene and evaluated their therapeutic efficacy in two models of pulmonary fibrosis: a model induced by bleomycin and a novel model of the disease developed spontaneously in mice overexpressing the full length of human TGF-β1 in the lungs. Intrapulmonary delivery of aerosolized siRNAs of TGF-β1 with sequences common to humans and rodents significantly inhibited bleomycin-induced pulmonary fibrosis in the acute and chronic phases of the disease and in a dose-dependent manner. Aerosolized human-specific siRNA also efficiently inhibited pulmonary fibrosis, improvedlung function,andprolonged survival in human TGF-β1 transgenic mice. Mice showed no off-target effects after intratracheal administration of siRNA. These results suggest the applicability of these novel siRNAs as tools for treating pulmonary fibrosis in humans.

Original languageEnglish (US)
Pages (from-to)397-406
Number of pages10
JournalAmerican journal of respiratory cell and molecular biology
Issue number3
StatePublished - Mar 1 2012


  • Growth factors
  • Idiopathic pulmonary fibrosis
  • RNA interference

ASJC Scopus subject areas

  • Molecular Biology
  • Pulmonary and Respiratory Medicine
  • Clinical Biochemistry
  • Cell Biology


Dive into the research topics of 'Development and preclinical efficacy of novel transforming growth factor-β1 short interfering RNAs for pulmonary fibrosis'. Together they form a unique fingerprint.

Cite this